Victory Capital Management Inc. Sells 9,832 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Victory Capital Management Inc. trimmed its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 43.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,674 shares of the life sciences company’s stock after selling 9,832 shares during the period. Victory Capital Management Inc.’s holdings in Integra LifeSciences were worth $287,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. KBC Group NV boosted its holdings in Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after acquiring an additional 1,120 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares during the period. Empowered Funds LLC bought a new stake in Integra LifeSciences during the fourth quarter valued at about $180,000. Romano Brothers AND Company bought a new stake in Integra LifeSciences during the fourth quarter valued at about $204,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in Integra LifeSciences during the fourth quarter valued at about $204,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Down 1.0 %

NASDAQ IART opened at $22.49 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm has a 50-day simple moving average of $23.85 and a 200 day simple moving average of $22.05. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $35.49. The stock has a market cap of $1.74 billion, a PE ratio of -249.86, a PEG ratio of 0.73 and a beta of 1.23.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter last year, the company earned $0.89 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. On average, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley began coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.